{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:57:33Z","timestamp":1781607453499,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["WT-219429\/Z\/19\/Z."],"award-info":[{"award-number":["WT-219429\/Z\/19\/Z."]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["WT-219429\/Z\/19\/Z."],"award-info":[{"award-number":["WT-219429\/Z\/19\/Z."]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["WT-219429\/Z\/19\/Z."],"award-info":[{"award-number":["WT-219429\/Z\/19\/Z."]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["WT-219429\/Z\/19\/Z."],"award-info":[{"award-number":["WT-219429\/Z\/19\/Z."]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Long-Acting injectable (LAI) antipsychotics prevent relapse in patients with unreliable adherence to oral antipsychotics. Non-engagement with treatment is associated with relapse and involuntary admission. Financial incentives have been shown to increase engagement with LAI antipsychotics among those at highest risk of relapse. This study aimed to explore whether community mental health professionals who deliver LAI antipsychotics find financial incentives acceptable and whether empirical research has addressed their concerns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Fourteen mental health professionals who deliver LAI antipsychotics were interviewed after snowball recruitment. Each then saw a presentation outlining recent research findings into financial incentives for LAI antipsychotic engagement before interviews resumed. Interviews explored the advantages and challenges professionals anticipated with respect to financial incentives for LAIs. Thematic analysis was conducted and themes were compared with findings from the literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Median self-reported support increased from \u201c5\/10\u201d to \u201c6.75\/10\u201d after the information presentation. Participants responded positively to the idea that incentives could be seen as \u2018rewards\u2019. They readily drew connections between improvements in engagement, increased insight, and stronger therapeutic relationships. Practical implementation challenges were envisioned along with proposed solutions. Several participants remained concerned that financial incentives would lead to increased drug use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Mental health professionals who deliver LAI antipsychotics hold a range of views about the potential role of financial incentives to increase engagement. When professionals are aware of research findings they are more positive about incentives. Further research should consider patients\u2019 and professionals\u2019 preferences for the design of incentive regimes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12888-025-07165-9","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T07:54:28Z","timestamp":1755503668000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Financial incentives and long-acting injectable antipsychotics engagement: community mental health professionals\u2019 perspectives"],"prefix":"10.1186","volume":"25","author":[{"given":"Nathan","family":"Hodson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madiha","family":"Majid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Vlaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swaran","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"key":"7165_CR1","volume-title":"Practice guideline for the treatment of patients with schizophrenia","author":"GA Keepers","year":"2021","unstructured":"Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojatabai R, Servis M, Walaszek A, Buckley P, Lenzenweger MF, Young AS, Degenhardt A. Practice guideline for the treatment of patients with schizophrenia. 3 ed. Washington, DC: American Psychiatric Association; 2021.","edition":"3"},{"issue":"9","key":"7165_CR2","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1177\/0706743717720448","volume":"62","author":"G Remington","year":"2017","unstructured":"Remington G, et al. Guidelines for the pharmacotherapy of schizophrenia in adults. Can J Psychiatry. 2017;62(9):604\u201316.","journal-title":"Can J Psychiatry"},{"key":"7165_CR3","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/1471-244X-13-340","volume":"13","author":"PM Llorca","year":"2013","unstructured":"Llorca PM, et al. Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry. 2013;13:340.","journal-title":"BMC Psychiatry"},{"issue":"Suppl 1","key":"7165_CR4","first-page":"S19","volume":"59","author":"S Grover","year":"2017","unstructured":"Grover S, et al. Clinical practice guidelines for management of schizophrenia. Indian J Psychiatry. 2017;59(Suppl 1):S19\u201333.","journal-title":"Indian J Psychiatry"},{"key":"7165_CR5","unstructured":"Psychosis and schizophrenia in adults: prevention and management, in Clinical Guidelines. 2014, National Institute for Health and Care Excellence: London, UK. p. 1.5.5.3."},{"issue":"7","key":"7165_CR6","doi-asserted-by":"publisher","first-page":"e2224163","DOI":"10.1001\/jamanetworkopen.2022.24163","volume":"5","author":"Y Wei","year":"2022","unstructured":"Wei Y, et al. Association of long-acting injectable antipsychotics and oral antipsychotics with disease relapse, health care use, and adverse events among people with schizophrenia. JAMA Netw Open. 2022;5(7):e2224163.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"7165_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1524-4733.2007.00214.x","volume":"11","author":"J Ahn","year":"2008","unstructured":"Ahn J, et al. Classifying patients by antipsychotic adherence patterns using latent class analysis: characteristics of nonadherent groups in the California medicaid (Medi-Cal) program. Value Health. 2008;11(1):48\u201356.","journal-title":"Value Health"},{"key":"7165_CR8","doi-asserted-by":"publisher","first-page":"269","DOI":"10.2147\/NDT.S97883","volume":"12","author":"EL Noordraven","year":"2016","unstructured":"Noordraven EL, et al. Depot-medication compliance for patients with psychotic disorders: the importance of illness insight and treatment motivation. Neuropsychiatr Dis Treat. 2016;12:269\u201374.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"6","key":"7165_CR9","first-page":"43","volume":"5","author":"A Camacho","year":"2008","unstructured":"Camacho A, et al. Use of Risperidone long-acting injectable in a rural border community clinic in Southern California. Psychiatry (Edgmont). 2008;5(6):43\u20139.","journal-title":"Psychiatry (Edgmont)"},{"key":"7165_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1471-244X-8-32","volume":"8","author":"G Morken","year":"2008","unstructured":"Morken G, Widen JH, Grawe RW. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry. 2008;8:32.","journal-title":"BMC Psychiatry"},{"issue":"1","key":"7165_CR11","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1186\/s12889-019-7407-8","volume":"19","author":"I Vlaev","year":"2019","unstructured":"Vlaev I, et al. Changing health behaviors using financial incentives: a review from behavioral economics. BMC Public Health. 2019;19(1):1059.","journal-title":"BMC Public Health"},{"key":"7165_CR12","doi-asserted-by":"publisher","first-page":"f5847","DOI":"10.1136\/bmj.f5847","volume":"347","author":"S Priebe","year":"2013","unstructured":"Priebe S, et al. Effectiveness of financial incentives to improve adherence to maintenance treatment with antipsychotics: cluster randomised controlled trial. BMJ. 2013;347:f5847.","journal-title":"BMJ"},{"issue":"3","key":"7165_CR13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S2215-0366(17)30045-7","volume":"4","author":"EL Noordraven","year":"2017","unstructured":"Noordraven EL, et al. Financial incentives for improving adherence to maintenance treatment in patients with psychotic disorders (Money for Medication): a multicentre, open-label, randomised controlled trial. Lancet Psychiatry. 2017;4(3):199\u2013207.","journal-title":"Lancet Psychiatry"},{"key":"7165_CR14","doi-asserted-by":"crossref","unstructured":"Barankay I, et al. Effect of patient financial incentives on Statin adherence and lipid control: a randomized clinical trial. JAMA Netw Open. 2020;3(10):e2019429.","DOI":"10.1001\/jamanetworkopen.2020.19429"},{"issue":"2","key":"7165_CR15","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/archpsyc.63.2.201","volume":"63","author":"JM Peirce","year":"2006","unstructured":"Peirce JM, et al. Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: a National drug abuse treatment clinical trials network study. Arch Gen Psychiatry. 2006;63(2):201\u20138.","journal-title":"Arch Gen Psychiatry"},{"issue":"8","key":"7165_CR16","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1136\/jme.2009.035071","volume":"36","author":"S Priebe","year":"2010","unstructured":"Priebe S, et al. Acceptability of offering financial incentives to achieve medication adherence in patients with severe mental illness: a focus group study. J Med Ethics. 2010;36(8):463\u20138.","journal-title":"J Med Ethics"},{"issue":"2","key":"7165_CR17","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/JCP.0000000000000276","volume":"35","author":"E Highton-Williamson","year":"2015","unstructured":"Highton-Williamson E, et al. Offering financial incentives to increase adherence to antipsychotic medication: the clinician experience. J Clin Psychopharmacol. 2015;35(2):120\u20137.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"7165_CR18","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s12888-017-1485-x","volume":"17","author":"EL Noordraven","year":"2017","unstructured":"Noordraven EL, et al. Ethical acceptability of offering financial incentives for taking antipsychotic depot medication: patients\u2019 and clinicians\u2019 perspectives after a 12-month randomized controlled trial. BMC Psychiatry. 2017;17(1):313.","journal-title":"BMC Psychiatry"},{"issue":"5","key":"7165_CR19","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/j.1365-2850.2010.01550.x","volume":"17","author":"C Besenius","year":"2010","unstructured":"Besenius C, Clark-Carter D, Nolan P. Health professionals\u2019 attitudes to depot injection antipsychotic medication: a systematic review. J Psychiatr Ment Health Nurs. 2010;17(5):452\u201362.","journal-title":"J Psychiatr Ment Health Nurs"},{"key":"7165_CR20","doi-asserted-by":"publisher","first-page":"e059526","DOI":"10.1136\/bmjopen-2021-059526","volume":"12","author":"N Hodson","year":"2022","unstructured":"Hodson N, Vlaev MM, Singh I. Can incentives improve antipsychotic adherence in major mental illness? A mixed-methods systematic review. BMJ Open. 2022;12:e059526.","journal-title":"BMJ Open"},{"issue":"4","key":"7165_CR21","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1007\/s11135-017-0574-8","volume":"52","author":"B Saunders","year":"2018","unstructured":"Saunders B, et al. Saturation in qualitative research: exploring its conceptualization and operationalization. Qual Quant. 2018;52(4):1893\u2013907.","journal-title":"Qual Quant"},{"issue":"5","key":"7165_CR22","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0253717620946111","volume":"42","author":"C Andrade","year":"2020","unstructured":"Andrade C, et al. Designing and conducting knowledge, attitude, and practice surveys in psychiatry: practical guidance. Indian J Psychol Med. 2020;42(5):478\u201381.","journal-title":"Indian J Psychol Med"},{"issue":"9","key":"7165_CR23","doi-asserted-by":"publisher","first-page":"e011673","DOI":"10.1136\/bmjopen-2016-011673","volume":"6","author":"S Priebe","year":"2016","unstructured":"Priebe S, Bremner SA, Pavlickova H. Discontinuing financial incentives for adherence to antipsychotic depot medication: long-term outcomes of a cluster randomised controlled trial. BMJ Open. 2016;6(9):e011673.","journal-title":"BMJ Open"},{"key":"7165_CR24","doi-asserted-by":"crossref","unstructured":"Hodson N, et al. Take patients seriously when they say financial incentives help with adherence. BJPsych Bull. 2023;47(3):149\u201352.","DOI":"10.1192\/bjb.2022.76"},{"key":"7165_CR25","unstructured":"Joint_Formulary_Committee. British National formulary. London, UK: BMJ and Pharmaceutical; 2022."},{"issue":"1","key":"7165_CR26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.64719\/pb.4285","volume":"43","author":"AB Staring","year":"2010","unstructured":"Staring AB, Mulder CL, Priebe S. Financial incentives to improve adherence to medication in five patients with schizophrenia in the Netherlands. Psychopharmacol Bull. 2010;43(1):5\u201310.","journal-title":"Psychopharmacol Bull"},{"issue":"3","key":"7165_CR27","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00127-015-1165-4","volume":"51","author":"A Malla","year":"2016","unstructured":"Malla A, et al. From early intervention in psychosis to youth mental health reform: a review of the evolution and transformation of mental health services for young people. Soc Psychiatry Psychiatr Epidemiol. 2016;51(3):319\u201326.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"issue":"5","key":"7165_CR28","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1017\/S204579601800063X","volume":"28","author":"A Crowther","year":"2019","unstructured":"Crowther A, et al. The impact of recovery colleges on mental health staff, services and society. Epidemiol Psychiatr Sci. 2019;28(5):481\u20138.","journal-title":"Epidemiol Psychiatr Sci"},{"issue":"8","key":"7165_CR29","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1007\/s11136-016-1238-1","volume":"25","author":"K Moran","year":"2016","unstructured":"Moran K, Priebe S. Better quality of life in patients offered financial incentives for taking anti-psychotic medication: linked to improved adherence or more money? Qual Life Res. 2016;25(8):1897\u2013902.","journal-title":"Qual Life Res"},{"key":"7165_CR30","doi-asserted-by":"publisher","first-page":"105762","DOI":"10.1016\/j.ypmed.2019.105762","volume":"126","author":"K Hoskins","year":"2019","unstructured":"Hoskins K, et al. Acceptability of financial incentives for health-related behavior change: an updated systematic review. Prev Med. 2019;126:105762.","journal-title":"Prev Med"},{"issue":"2","key":"7165_CR31","doi-asserted-by":"publisher","first-page":"e0170686","DOI":"10.1371\/journal.pone.0170686","volume":"12","author":"E Greene","year":"2017","unstructured":"Greene E, et al. It makes you feel like someone cares acceptability of a financial incentive intervention for HIV viral suppression in the HPTN 065 (TLC-Plus) study. PLoS One. 2017;12(2):e0170686.","journal-title":"PLoS One"},{"issue":"19","key":"7165_CR32","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1016\/j.vaccine.2016.03.009","volume":"34","author":"RJ McNaughton","year":"2016","unstructured":"McNaughton RJ, Adams J, Shucksmith J. Acceptability of financial incentives or quasi-mandatory schemes to increase uptake of immunisations in preschool children in the United Kingdom: qualitative study with parents and service delivery staff. Vaccine. 2016;34(19):2259\u201366.","journal-title":"Vaccine"},{"issue":"1","key":"7165_CR33","doi-asserted-by":"publisher","first-page":"e0279128","DOI":"10.1371\/journal.pone.0279128","volume":"18","author":"B Abdelazeem","year":"2023","unstructured":"Abdelazeem B, et al. Does usage of monetary incentive impact the involvement in surveys? A systematic review and meta-analysis of 46 randomized controlled trials. PLoS One. 2023;18(1):e0279128.","journal-title":"PLoS One"},{"issue":"2","key":"7165_CR34","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jsat.2014.03.001","volume":"47","author":"DS Festinger","year":"2014","unstructured":"Festinger DS, et al. Contingency management for cocaine treatment: cash vs. vouchers. J Subst Abuse Treat. 2014;47(2):168\u201374.","journal-title":"J Subst Abuse Treat"},{"issue":"10","key":"7165_CR35","doi-asserted-by":"publisher","first-page":"e37184","DOI":"10.2196\/37184","volume":"9","author":"D Guinart","year":"2022","unstructured":"Guinart D, et al. A digital intervention using daily financial incentives to increase medication adherence in severe mental illness: single-arm longitudinal pilot study. JMIR Ment Health. 2022;9(10):e37184.","journal-title":"JMIR Ment Health"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-07165-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-025-07165-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-07165-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:41:33Z","timestamp":1781606493000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12888-025-07165-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7165"],"URL":"https:\/\/doi.org\/10.1186\/s12888-025-07165-9","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,18]]},"assertion":[{"value":"18 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval obtained from Coventry and Warwickshire NHS Partnership Trust and from University of Warwick Biomedical Sciences Research Ethics Committee. Informed consent to participate was obtained from every participant at the start of each interview.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants gave informed consent to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"791"}}